Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

8.91USD
20 Apr 2018
Change (% chg)

$0.16 (+1.83%)
Prev Close
$8.75
Open
$8.72
Day's High
$9.00
Day's Low
$8.55
Volume
50,199
Avg. Vol
59,258
52-wk High
$23.68
52-wk Low
$7.85

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $188.25
Shares Outstanding(Mil.): 21.10
Dividend: --
Yield (%): --

Financials

  PTGX.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -2.16 -- --
ROI: -35.41 -0.71 13.13
ROE: -35.50 -2.76 14.96

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

Mar 26 2018

BRIEF-Protagonist Therapeutics Q4 Loss Per Share $0.15

* PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Mar 07 2018

BRIEF-FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300

* FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA Source text for Eikon: Further company coverage:

Mar 06 2018

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

Jan 04 2018

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Dec 14 2017

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

Dec 14 2017

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

Nov 09 2017

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

Nov 06 2017

Earnings vs. Estimates